4.5 Article

The impact of elevated serum IgG4 levels in patients with primary sclerosing cholangitis

Journal

DIGESTIVE AND LIVER DISEASE
Volume 46, Issue 10, Pages 903-908

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.dld.2014.06.010

Keywords

IgG4 status; Prevalence; Survival

Funding

  1. Medical Research Council of Vastra Gotaland in Sweden [ALF-22101]
  2. Rolf Olsson Memorial Scholarship Fund
  3. German Research Community [MU 2864/1-1]

Ask authors/readers for more resources

Background: Elevated IgG4 levels have been reported among patients with primary sclerosing cholangitis. Epidemiological data has only been provided from tertiary centres. Aims: To investigate the prevalence of elevated IgG4 levels and to compare prognosis between patients with and without elevated IgG4 levels in serum in two European cohorts of patients with primary sclerosing cholangitis. Methods: Serum IgG4-levels were measured in a consecutive series of patients from Berlin, and retrospectively collected in a population-based cohort from Sweden (total N = 345). Cox's proportional hazard analysis was used to calculate relative risks for liver-related death or liver transplantation and cholangiocarcinoma. Results: Elevated IgG4 values were demonstrated in 10% of patients. A previous history of pancreatitis, combined intra-and extrahepatic biliary involvement and jaundice were independently associated with elevated IgG4 in multivariate analysis. IgG4 status was not associated with an increased risk for the combined endpoint liver-related death or liver transplantation or cholangiocarcinoma. Conclusion: The prevalence of elevated IgG4 values among European patients with primary sclerosing cholangitis is similar to what previously has been reported from the United States. Elevated IgG4 was not associated with an increased risk of liver transplantation or liver-related death or cholangiocarcinoma. (C) 2014 Editrice Gastroenterologica Italiana S. r. l. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Radiology, Nuclear Medicine & Medical Imaging

Evaluation of response in patients with hepatocellular carcinoma treated with intratumoral dendritic cell vaccination using intravoxel incoherent motion (IVIM) MRI and histogram analysis

Mats Andersson, Oscar Jalnefjord, Mikael Montelius, Magnus Rizell, Malin Sternby Eilard, Maria Ljungberg

Summary: This study evaluated the response to intratumoral injections with the immune primer, ilixadencel, in hepatocellular carcinoma (HCC) using diffusion-weighted magnetic resonance imaging (DW-MRI) and intravoxel incoherent motion (IVIM) with histogram analysis. The results showed significant reductions in the perfusion-related parameter D* after ilixadencel injections, as well as correlations between baseline D values and tumor size change at three months. Further research is needed to confirm these findings and explore the treatment effect on HCC.

ACTA RADIOLOGICA (2023)

Article Immunology

End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT fiares in chronic hepatitis B patients

Sylvia M. Brakenhoff, Margo J. H. van Campenhout, Annemiek A. van der Eijk, Willem P. Brouwer, Florian van Bommel, Bettina E. Hansen, Thomas Berg, Harry L. A. Janssen, Robert A. de Man, Milan J. Sonneveld

Summary: The study aimed to investigate the relationship between off-treatment ALT flares and virological outcomes, as well as to explore whether serum levels of novel biomarkers at the end of treatment can predict flares. The results showed that ALT flares were associated with decreased sustained response rates, and higher levels of HBsAg, HBV RNA, and HBcrAg were associated with an increased risk of flares.

JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2023)

Article Gastroenterology & Hepatology

Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma

Philipp K. Haber, Florian Castet, Miguel Torres-Martin, Carmen Andreu-Oller, Marc Puigvehi, Maeda Miho, Pompilia Radu, Jean-Francois Dufour, Chris Verslype, Carolin Zimpel, Jens U. Marquardt, Peter R. Galle, Arndt Vogel, Melanie Bathon, Tim Meyer, Ismail Labgaa, Antonia Digklia, Lewis R. Roberts, Mohamed A. Mohamed Ali, Beatriz Minguez, Davide Citterio, Vincenzo Mazzaferro, Fabian Finkelmeier, Joerg Trojan, Burcin Ozdirik, Tobias Mueller, Moritz Schmelzle, Anthony Bejjani, Max W. Sung, Myron E. Schwartz, Richard S. Finn, Swan Thung, Augusto Villanueva, Daniela Sia, Josep M. Llovet

Summary: This study analyzed tumor samples from patients with advanced hepatocellular carcinoma (aHCC) treated with anti-PD1 and identified interferon signaling and major histocompatibility complex-related genes as key molecular features of HCCs responding to anti-PD1. The researchers developed an 11-gene signature that can predict treatment response and survival in frontline aHCC patients.

GASTROENTEROLOGY (2023)

Article Gastroenterology & Hepatology

Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure

Julia Dietz, Beat Muellhaupt, Peter Buggisch, Christiana Graf, Kai-Henrik Peiffer, Katrin Matschenz, Joern M. Schattenberg, Christoph Antoni, Stefan Mauss, Claus Niederau, Thomas Discher, Janina Trauth, Georg Dultz, Julian Schulze zur Wiesch, Felix Piecha, Hartwig Klinker, Tobias Mueller, Thomas Berg, Christoph Neumann-Haefelin, Christoph P. Berg, Stefan Zeuzem, Christoph Sarrazin

Summary: This study evaluated the long-term persistence of resistance-associated substitutions (RASs) in HCV patients treated with DAAs. Low-to medium-level RASs were found to persist over time, while high-level resistant RASs gradually disappeared. Different patterns of RAS persistence according to HCV subtype could have implications for retreatment with first-generation DAAs and for global HCV elimination goals.

JOURNAL OF HEPATOLOGY (2023)

Article Medicine, General & Internal

Association of Alpha-1 Antitrypsin Pi*Z Allele Frequency and Progressive Liver Fibrosis in Two Chronic Hepatitis C Cohorts

Victoria Therese Muecke, Janett Fischer, Marcus Maximilian Muecke, Alexander Teumer, Alexander Koch, Johannes Vermehren, Malin Fromme, Stefan Zeuzem, Christian Trautwein, Christoph Sarrazin, Thomas Berg, Biaohuan Zhou, Karim Hamesch

Summary: This study found that the heterozygous Pi*Z allele is not a clinically relevant disease modifier in chronic hepatitis C infection, based on analysis of two cohorts. Further validation in larger cohorts with longitudinal follow-up is needed.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Oncology

Transcriptomic Deconvolution of Neuroendocrine Neoplasms Predicts Clinically Relevant Characteristics

Raik Otto, Katharina M. Detjen, Pamela Riemer, Melanie Fattohi, Carsten Groetzinger, Guido Rindi, Bertram Wiedenmann, Christine Sers, Ulf Leser

Summary: Machine learning approaches can improve the classification accuracy of neuroendocrine neoplasms (NEN), but usually require large amounts of training data. This study used machine learning-aided classification based on the similarity between NEN and non-transformed pancreatic cell types to predict patient survival time, neoplastic grading, and carcinoma versus tumor subclassification, providing additional criteria for confident classification of ambiguous cases.

CANCERS (2023)

Article Microbiology

Association of Common Polymorphisms in the Interleukin-1 Beta Gene with Hepatocellular Carcinoma in Caucasian Patients with Chronic Hepatitis B

Janett Fischer, Shuang Long, Eleni Koukoulioti, Tobias Mueller, Balazs Fueloep, Renate Heyne, Mohammed Eslam, Jacob George, Fabian Finkelmeier, Oliver Waidmann, Thomas Berg, Florian van Boemmel

Summary: This study found that three common IL-1 beta SNPs are associated with HBV-related HCC in Caucasian patients, with rs1143627 TT and rs16944 CC genotypes being more frequent in HCC patients.

PATHOGENS (2023)

Article Oncology

Intratumoral dendritic cells and T cells predict survival in gastroenteropancreatic neuroendocrine neoplasms

Wiebke Werner, Katharina Detjen, Alix Bruneau, Isabella Lurje, Natalie Nestel, Henning Jann, Frank Tacke, Bertram Wiedenmann, Christoph Roderburg, Linda Hammerich

Summary: In a retrospective study on neuroendocrine tumors, the levels of FLT3LG mRNA were found to be correlated with the abundance of immune cells cDC and T cells, which also predicted disease-specific survival. The combination of FLT3LG and T cell counts improved this prediction, suggesting their potential as prognostic markers.

ENDOCRINE-RELATED CANCER (2023)

Article Oncology

Osteopontin is a prognostic circulating biomarker in patients with neuroendocrine neoplasms

Evelyn Kidess, Yvonne Giesecke, Ines Eichhorn, Raphael Mohr, Henning Jann, Christian Fischer, Bertram Wiedenmann, Christoph Roderburg, Frank Tacke, Michael Sigal

Summary: The study aimed to analyze plasma concentrations of OPN in patients with NEN and explore its diagnostic and prognostic value. The results showed that OPN levels were significantly higher in NEN patients compared to healthy controls, with the highest levels in high-grade tumors (grade 3). In addition, patients with initial OPN levels above 200 ng/ml had a poor prognosis in terms of shorter progression-free survival, both in the overall NEN patient group and within the subgroup of well-differentiated G1/G2 tumors. Therefore, OPN can serve as a surrogate prognostic biomarker in NEN patients.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Editorial Material Gastroenterology & Hepatology

The future of hepatology - The best way to predict the future is to create it

Thomas Berg, Aleksander Krag

JOURNAL OF HEPATOLOGY (2023)

Letter Gastroenterology & Hepatology

Reply letter regarding concerning issues in evaluating the inter-rater reliability. Comment on 'risk factors for underestimation of patient pain in outpatient colonoscopy by ryhlander et al.' by Yu et al.

Jessica Ryhlander, Gisela Ringstrom, Bjorn Lindkvist, Viktor Tasselius, Per Hedenstrom

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2023)

Review Oncology

Systemic treatment in patients with Child-Pugh B liver dysfunction and advanced hepatocellular carcinoma

Frederico Costa, Bertram Wiedenmann, Christoph Roderburg, Raphael Mohr, Ghassan K. Abou-Alfa

Summary: Hepatocellular carcinoma (HCC) is a leading cause of death in liver cirrhosis patients. Immuno-oncology has revolutionized the treatment for advanced HCC, but most trials exclude patients with moderate liver dysfunction. Patients with HCC and moderate liver dysfunction have a low overall survival rate with sorafenib treatment, indicating the need for improved treatment strategies.

CANCER MEDICINE (2023)

Article Health Care Sciences & Services

Revising the MELD Score to Address Sex-Bias in Liver Transplant Prioritization for a German Cohort

Maria Beatriz Walter Costa, Christiane Gaertner, Maria Schmidt, Thomas Berg, Daniel Seehofer, Thorsten Kaiser

Summary: The MELD scoring system used in prioritizing liver transplantation in Germany is biased against women. By substituting female patients' creatinine levels with male equivalents, we identified a potential solution to reduce gender inequality in patient prioritization for liver transplantation.

JOURNAL OF PERSONALIZED MEDICINE (2023)

Article Gastroenterology & Hepatology

Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial

Max Seidensticker, Osman Oecal, Kerstin Schuette, Peter Malfertheiner, Thomas Berg, Christian Loewe, Heinz Josef Kluempen, Otto van Delden, Muzaffer Reha Uemuetlue, Najib Ben Khaled, Enrico Narciso de Toni, Ricarda Seidensticker, Ali Aghdassi, Albert Tran, Jean-Pierre Bronowicki, Bora Peynircioglu, Bruno Sangro, Maciej Pech, Jens Ricke

Summary: This study aimed to evaluate the efficacy and safety of adjuvant sorafenib treatment compared with placebo in hepatocellular carcinoma patients who underwent local ablation. The results showed that adjuvant sorafenib did not improve time-to-recurrence or local control rate in patients with hepatocellular carcinoma after local ablation.

JHEP REPORTS (2023)

Letter Gastroenterology & Hepatology

Reply to: Depiction of alcohol-related liver disease in the EASL International Liver Congress

Tobias Boettler, Aleksander Krag, Thomas Berg

JOURNAL OF HEPATOLOGY (2023)

No Data Available